Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B and D Data Accepted for Presentation at EASL™ Congress 2023
SAN FRANCISCO, June 07, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that five abstracts highlighting new data from the Company’s broad hepatitis portfolio addressing both hepatitis B virus (HBV) and hepatitis D virus (HDV) have been accepted for presentation at the annual meeting of the European Association for the Study of the Liver, EASL™ Congress 2023, taking place in Vienna from June 21-24.
“The accepted abstracts underscore the progress Vir is making with our robust hepatitis B and D portfolio and the potential impact the combination of VIR-3434 and VIR-2218 could have on both viruses,” said Phil Pang, M.D., Ph.D., Vir’s Executive Vice President, Chief Medical Officer and Interim Head of Research. “We look forward to sharing new data from our clinical development programs that give us confidence in our approach toward a functional cure for HBV and a treatment for the long-term suppression of HDV.”
The late-breaker oral presentation, which was accepted as the only HBV-focused late-breaker abstract, will provide new data related to the safety and efficacy of VIR-2218 with or without pegylated interferon alfa (PEG-IFN-a) in virally-suppressed participants with chronic HBV infection.
A second oral presentation will share follow-up data from Part A of the Phase 2 MARCH trial. Originally presented at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® in November 2022, Part A was designed to, and successfully demonstrated, the on-treatment additivity of VIR-2218 and VIR-3434. Importantly, these short-duration Part A cohorts, in which these investigational treatments were co-administered for only four or 12 weeks, informed the protocol for Part B, which is designed to evaluate whether VIR-3434 and VIR-2218, given with or without PEG-IFN-a for 24 and 48 weeks, can result in a functional cure for chronic HBV. Initial on-treatment data from the 24-week cohorts are anticipated in the second half of 2023.
Finally, three poster presentations will focus on the potential efficacy of VIR-2218 and VIR-3434 in preclinical models of HDV, the pharmacokinetics of HBV monotherapy with VIR-3434, and the eligibility and initiation of HBV treatment in a real-world setting.
Presentation details are as follows:
Late-Breaker Oral Presentation
The EASL presentation abstracts can be accessed under Events & Presentations in the Investors section of the Vir website here.
About Chronic Hepatitis B
About Chronic Hepatitis D
About Vir Biotechnology
Contact: Carly Scaduto Senior Director, Media Relations [email protected] +1-314-368-5189
IDEA Showcase Startup Pitches & Reception
Special Presentation TBA
Solutions Showcase Session